Citigroup
NVLN

Citigroup’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

Citigroup’s Portfolio NVLN Stock Details NVLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-2,220
Closed -$19K – 7429
2016
Q4 		$19K Buy
+2,220
New +$19.7K ﹤0.01% 6551

Other funds holding NVLN

EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citigroup's NVLN Position: Q4 2018 in Review

Citigroup sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q4 2018, closing a stake of 1,100 shares — an estimated $3K sold.

Citigroup first reported a position in NVLN in Q4 2016 and held it in 8 quarters. The position peaked at $124K in Q2 2018. 36 funds tracked by Wall St. Rank hold NVLN as of Q4 2018.

  • Citigroup reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q4 2018 after selling out during the quarter.
  • Citigroup sold 1,100 Novelion Therapeutics Inc. Common Shares shares in Q4 2018, an estimated $3K.
  • Citigroup first reported a position in Novelion Therapeutics Inc. Common Shares in Q4 2016 and held it in 8 quarters.
  • Citigroup's Novelion Therapeutics Inc. Common Shares position peaked at $124K in Q2 2018.
  • 36 funds tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q4 2018.

Based on Citigroup's 13F filing for Q4 2018, filed 12 Feb 2019.